A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GVHD / graft-versus-host disease

[Related PubMed/MEDLINE]
Total Number of Papers: 11529
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   GVHD  (>> Co-occurring Abbreviation)
Long Form:   graft-versus-host disease
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 "Is this the GVHD?" A qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service. BMT, QoL
2021 A bi-centric experience of extracorporeal carbon dioxide removal (ECCO2 R) for acute hypercapnic respiratory failure following allogeneic hematopoietic stem cell transplantation. ARF, HSCT
2021 A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin. ATG, sGVHD, SHR, sIL-2Ralpha
2021 A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. allo-HCT, FOSs, SCFAs
2021 A Large-Scale Bank of Organ Donor Bone Marrow and Matched Mesenchymal Stem Cells for Promoting Immunomodulation and Transplant Tolerance. BM, HPC, HSPC, SOT, vBA-MSC, VCA
2021 A novel endogenous CD16-Expressing Natural Killer Cell for cancer immunotherapy. ADCC, CRS, NK
2021 A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology. ACC, CAR, CRS, HER2, NK, oNK
2021 A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. aGVHD, cGVHD, CI, haploHCT, HCT, MMF, NIH, PB, PTCy
2021 A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. aGVHD, CI, HR, MSD, TCZ, VUD
10  2021 A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma. ATL, HLA, PBSCT, PTCy
11  2021 A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients. allo-SCT
12  2021 A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. CI, HCT, OM, OS, RR
13  2021 A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key. HCT
14  2021 A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD. allo-HCT
15  2021 A survey of accuracy of nurses' clinical judgement of cutaneous graft-versus-host disease in Japan. CTCAE
16  2021 Activation of natural killer T cells enhances the function of regulatory T-cell therapy in suppressing murine GVHD. alpha-GalCer, iNKT, WT
17  2021 Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. CI, HCT, HR, NRM
18  2021 Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. ERC
19  2021 Acute Kidney Injury in the Modern Era of Allogeneic Hematopoietic Stem Cell Transplantation. AKI
20  2021 Acute pancreatitis following allogeneic hematopoietic stem cell transplantation in children. AP, CI, HSCT
21  2021 Acute Pulmonary Graft-Versus-Host Disease in a Patient with Adult T-cell Leukemia-Lymphoma Diagnosed by a Cryobiopsy. ---
22  2021 Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival. allo-HSCT, ATG, BMSC, GRFS, MUD, PBSC
23  2021 Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies. allo-HCT, RIC
24  2021 Advances in Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria. AA, HSCT, PNH
25  2021 Advances in the treatment of graft-versus-host disease with immunomodulatory cells. allo-HSCT, CAR, MSCs
26  2021 Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. CAR, iNKT
27  2021 Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis. allo-HCT, FBM
28  2021 Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. allo-HCT, CBT, GRFS, HLA, LFS, MMUD, NRM, OS, PTCy
29  2021 Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma allo-HSCT, CR, ENKL, GVL
30  2021 Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. allo-SCT, ASCT, DLBCL, EFS, NRM, OS, R/R
31  2021 Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center. allo-SCT, BV, CPI, CR, OS, PR, SD
32  2021 Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. allo-SCT, DFS, ECOG, NK, OS
33  2021 Allogeneic stem cell transplantation with omidubicel in sickle cell disease. HSCT, SCD, UCB
34  2021 Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. allo-HCT, cHL, CIs, PFS, PTCy
35  2021 Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. allo-HCT, CI, CIBMTR, DFS, HR, NRM, OS, RIC, t-MDS, URD
36  2021 Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. DFS, HCT, HR, MDS, OS
37  2021 An Antithymocyte Globulin-Free Conditioning Regimen Using Fludarabine and Cyclophosphamide Is Associated with Good Outcomes in Patients Undergoing Matched Related Family Donor Transplantation for Aplastic Anemia. AA, aGVHD, ATG, CY, Flu, HSCT, MRD, OS
38  2021 An Examination of Cytomegalovirus, Socioeconomic Status, Race, and Ethnicity on Outcomes after Haploidentical Hematopoietic Transplantation. CI, CMV, HI, HR, HSCT, IMD, OS, SES
39  2021 An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT. ALC, HBV, Hib, HSCT, IgG, VPDs
40  2021 Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation. HSCT, PIRCHE, TCEs
41  2021 Analyzing the clinical outcomes of switching from cyclosporine to tacrolimus in pediatric hematopoietic stem cell transplantation. CNI, ES, HSCT, PRES
42  2021 Anti-Thymocyte Globulin Prophylaxis in Patients With Hematological Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: An Updated Meta-Analysis. allo-HSCT, ATG, EBV, GRFS, NRM, OS, RCTs, RFS
43  2021 Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT. GRFS, HCT
44  2021 Antimicrobial photodynamic therapy for recurrent herpes labialis in chronic graft-versus-host disease: A case report. aPDT, BMT, HHV-1
45  2021 Area-under-the-Curve-Based Mycophenolate Mofetil Dosage May Contribute to Decrease the Incidence of Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients. allo-HSCT, CsA, MMF, MPA, MTX, TDM
46  2021 Association Between Baseline Patient-Reported Outcomes and Complications of Hematopoietic Stem Cell Transplantation. HCT, OR, PROs, QoL
47  2021 Association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) single nucleotide polymorphism in donors with clinical outcome after allogeneic hematopoietic stem cell transplantation: a meta-analysis. allo-HSCT, CIs, CTLA-4, DFS, OS
48  2021 Association of obesity with mortality and clinical outcomes in children and adolescents with transplantation: A systematic review and meta-analysis. ---
49  2021 Association of recipient and donor interleukin 6 polymorphisms 174 and 597 with outcome after allogeneic hematopoietic stem cell transplantation in children. HSCT, IL-6, SNPs
50  2021 Associations between the Gut Microbiota, Immune Reconstitution, and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation. allo-HSCT, GM
51  2021 Azacitidine maintenance therapy post-allogeneic stem cell transplantation in poor-risk acute myeloid leukemia. AML, HSCT
52  2021 Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role? EC, HCT, SOS, TA-TMA
53  2021 Biomarkers of graft-vs-host disease: Understanding and applications for the future. HSCT
54  2021 Bone Health Outcomes at 1 Year after Hematopoietic Stem Cell Transplantation in a Heterogeneous Pediatric Population. BMD, DXA, HAZ, HSCT, RIC
55  2021 Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective-A Literature Review. allo-SCT, QoL
56  2021 Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study. ALL, BU, CY, MA, RFS, RIST, TBI, TRM
57  2021 CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. CAR, CRS, NK, TAAs, TME
58  2021 Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease. SASP
59  2021 Case Report: Calpainopathy Presenting After Bone Marrow Transplantation, With Studies of Donor Genetic Content in Various Tissue Types. ---
60  2021 Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD. allo-HSCT, AML, FCM, HMAs, irAEs, MDS, MRD, PD, ts, WT1
61  2021 Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma. allo-HCT, ARDS, auto-HCT, COVID-19, DLI, HL, PTLD
62  2021 CD26 expression on donor harvest as a risk predictive biomarker for developing Graft-versus-Host Disease post-Allogeneic Hematopoietic Stem Cell Transplantation: A tenyear followup study. ASCT
63  2021 CD34+ Stem Cell Selection and CD3+ T Cell Add-Back from Matched Unrelated Adult Donors in Children with Primary Immunodeficiencies and Hematological Diseases. BM, BW, HSCT, MUD, PBSCs, PIDs, PTLD
64  2021 CD52/GPI- T-Cells Are Enriched for Alloreactive Specificity and Predict Acute Graft-Versus-Host-Disease After Stem Cell Transplantation. ---
65  2021 Central Nervous System-related Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. allo-HSCT, CNS
66  2021 Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation. allo-HCT, OR
67  2021 Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. allo-HSCT, AML, CCI, MDS, OS
68  2021 Children admitted to a pediatric intensive care unit after hematopoietic stem cell transplantation: Analysis of survival and predictors of mortality. CI, HSCT, OR, PICU
69  2021 Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy. CAR
70  2021 Clarithromycin As an Alternative and Prophylactic Agent in a Hematopoietic Stem Cell Transplantation Patient. HSCT, ST
71  2021 Clinical characteristics and outcomes of toxoplasmosis among transplant recipients at two US academic medical centers. HSCT, SOT
72  2021 Clinical Development of Cell Therapies to Halt Lysosomal Storage Diseases: Results and Lessons Learned. LSDs
73  2021 Clinical development of natural killer cells expressing chimeric antigen receptors. CAR, NK
74  2021 Clinical impact of multiple DNA virus infections in nondepleted haploidentical and unrelated allogeneic hematopoietic stem cell transplantation. BKV, CI, CMV, haplo-HSCT, HR, PTCy, UD-HSCT
75  2021 Clinical Utility of the Detection of the Loss of the Mismatched HLA in Relapsed Hematological Patients After Haploidentical Stem Cell Transplantation With High-Dose Cyclophosphamide. DLIs, Haplo-HSCT
76  2021 Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease. AIH, CTLA-4, FOXP3, ICIs, irAEs, PD-1
77  2021 Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. ALL, CAR, CR, EMD
78  2021 Combination Treatment With Metformin and Tacrolimus Improves Systemic Immune Cellular Homeostasis by Modulating Treg and Th17 Imbalance. LT, Th1, Th17, Treg
79  2021 Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. HLA, KIR, MDS, SAA, UCB
80  2021 Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. AML, CBT, LFS, UD
81  2021 Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study. AML, CI, CR, HR, HSCT, MAC, MRD, NRM, OS, RFS, RIC
82  2021 Compound heterozygous DCLRE1C mutations lead to clinically typical Severe Combined Immunodeficiency presenting with Graft Versus Host Disease. BCG, SCID, STR
83  2021 Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. allo-HCT, CNI, RAPA, Treg
84  2021 Congenital Athymia: Genetic Etiologies, Clinical Manifestations, Diagnosis, and Treatment. SCID
85  2021 Conjunctival Matrix Metalloproteinase-9 Clinical Assessment in Early Ocular Graft versus Host Disease. DED, MMP-9, OSDI, ROC, TBUT
86  2021 Connective Tissue Growth Factor Is Overexpressed in Explant Lung Tissue and Broncho-Alveolar Lavage in Transplant-Related Pulmonary Fibrosis. BAL, BOS, CLAD, CTGF, qPCR, RAS
87  2021 Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells. HSCT, RIC, SCD
88  2021 Cost comparison of extracorporeal photopheresis technologies at the European Institute of Oncology. ECP, IEO
89  2021 Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy. allo-SCT, ASCT, PI3Ki
90  2021 CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells. IDAA, TCR, TIDE
91  2021 Critical roles of TLRs on the polarization of mesenchymal stem cells for cell therapy of viral infections: a notice for COVID-19 treatment. COVID-19, MSCs, TLRs
92  2021 Current Concepts and Advances in Graft-Versus-Host Disease Immunology. ---
93  2021 Current practice in nutrition after allogeneic hematopoietic stem cell transplantation - Results from a survey among hematopoietic stem cell transplant centers. allo-HSCT, PN
94  2021 Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies. HSCT
95  2021 Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. CAR
96  2021 Current Use of Total Body Irradiation in Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation. HSCT, TBI
97  2021 Cyclosporine A-related neurotoxicity after haploidentical hematopoietic stem cell transplantation in children with hematopathy. CsA, HID-HSCT
98  2021 Cytotoxic T lymphocyte antigen-4 regulates development of xenogenic graft versus host disease in mice via modulation of host immune responses induced by changes in human T cell engraftment and gene expression. CTLA-4, DEGs, xeno-GvHD
99  2021 Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies. HCT, MRD, MUD, UCB
100  2021 Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells. AMPK, Treg